Picture loading failed.

Anti-CTGF therapeutic antibody (Pre-made Pamrevlumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Pamrevlumab (INN; development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-424-1mg 1mg 3090
GMP-Bios-ab-424-10mg 10mg 21890
GMP-Bios-ab-424-100mg 100mg 148000
GMP-Bios-ab-424-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CTGF therapeutic antibody (Pre-made Pamrevlumab biosimilar,Whole mAb)
INN Name Pamrevlumab
TargetCTGF
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesFibroGen
Conditions Approvedna
Conditions ActiveDuchenne muscular dystrophy;Idiopathic pulmonary fibrosis;Pancreatic cancer
Conditions DiscontinuedDiabetic cardiomyopathy;Diabetic nephropathies;Diabetic neuropathies;Glioblastoma;Glomerulonephritis;Hepatic fibrosis
Development Techna